Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

small molecule drug conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (4) Antibody-Drug Conjugates (ADCs) (2) Drug Intermediate (1) Drug-Linker Conjugates for ADC (5) Radionuclide-Drug Conjugates (RDCs) (1) ADC Payload (1) Akt (1) Apoptosis (3) Biochemical Assay Reagents (5) DNA Alkylator/Crosslinker (1) Elastase (1) FAP (2) HSP (1) Integrin (1) Microtubule/Tubulin (3) mTOR (1) PARP (1) PI3K (1) PSMA (2) Toll-like Receptor (TLR) (1) Topoisomerase (2) TROP2 (1)
By Research Areas:	Cancer (20) Inflammation/Immunology (1)

By Targets:

ADC Linker (4)

Antibody-Drug Conjugates (ADCs) (2)

Drug Intermediate (1)

Drug-Linker Conjugates for ADC (5)

Radionuclide-Drug Conjugates (RDCs) (1)

ADC Payload (1)

Akt (1)

Apoptosis (3)

Biochemical Assay Reagents (5)

DNA Alkylator/Crosslinker (1)

Elastase (1)

FAP (2)

HSP (1)

Integrin (1)

Microtubule/Tubulin (3)

mTOR (1)

PARP (1)

PI3K (1)

PSMA (2)

Toll-like Receptor (TLR) (1)

Topoisomerase (2)

TROP2 (1)

By Research Areas:

Cancer (20)

Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

GMP Molecules

Targets Recommended: Drug Intermediate Drug Isomer Drug Derivative Small Interfering RNA (siRNA) Repulsive guidance molecule Drug Metabolite Antibody-Drug Conjugates (ADCs) ALCAM/CD166 Peptide-Drug Conjugates (PDCs) Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC ADC Linker

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-141598

Datopotamab deruxtecan (solution) 2 Publications Verification DS-1062 (solution); Dato-DXd (solution)	TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

HY-147340

TL033 Tirumotecan	Drug-Linker Conjugates for ADC	Cancer
TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .

HY-147340A

TL033 TFA Tirumotecan TFA	Drug-Linker Conjugates for ADC	Cancer
TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .

HY-13631EG

Deruxtecan MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-164729

FZ-AD005	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-147287

Glu-urea-Glu-NHS ester	PSMA Drug Intermediate	Cancer
Glu-urea-Glu-NHS ester is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu. Glu-urea-Glu-NHS ester can be used for synthesis of small-molecule prostate-specific membrane antigen (PSMA) inhibitors, imaging agents (such as PSMAi-PEG conjugates), and targeted drug delivery vehicles .

HY-175350

OncoFAP-GlyPro-MMAE OncoFAP glidotin	FAP Microtubule/Tubulin	Cancer
OncoFAP-GlyPro-MMAE is a FAP small molecule-drug conjugate (SMDC) with an IC₅₀ of 0.49  nM. OncoFAP-GlyPro-MMAE consists of a FAP Ligand OncoFAP (HY-145938), a Tubulin inhibitor (MMAE) (HY-15162) and a linker. OncoFAP-GlyPro-MMAE can be used for cancers like renal cancer research .

HY-W800659

Boc-Gly-Gly-NHS ester	ADC Linker	Others
Boc-Gly-Gly-NHS ester can be used to selectively attach small molecules to specific amino acid residues on proteins, creating conjugates that can be used for a variety of applications in drug discovery and diagnostic assays.

HY-15579G

MMAF Monomethylauristatin F	Microtubule/Tubulin ADC Payload	Cancer
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-178219

Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin Apoptosis	Cancer
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .

HY-179457

CC-11	PI3K mTOR Akt HSP	Cancer
CC-11 is an orally active small molecule drug conjugate (SMDC) that links the PI3K/mTOR inhibitor with the extracellular heat shock protein 90 (EHSP90) targeting ligand through a cleavable linker. CC-11 exhibits strong HSP90 binding activity (IC₅₀ = 15 nM) and inhibits PI3Kα kinase activity (IC₅₀ = 0.54 nM). CC-11 has anti-proliferative activity against colon cancer cells. CC-11 shows significant efficacy in the HCT-116 xenograft tumor model. CC-11 can be used for research on colon cancer .

HY-175353

TriOncoFAP-GlyPro-MMAE	FAP	Cancer
TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC₅₀ of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE) .

HY-20336G

Mc-Val-Cit-PABC-PNP	ADC Linker	Cancer
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-169336

CQ-16	PARP PSMA	Cancer
CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC₅₀=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W087187G

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-128952G

Tesirine SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-170842

TDK-HCPT	Apoptosis	Cancer
TDK-HCPT is a small-molecule conjugate that links glutathione-sensitive thiamine disulfide to the chemotherapy drug 10-Hydroxycamptothecin (HY-N0095) via a thioketal bond. TDK-HCPT can target tumor cells and prolong the retention of chemotherapy agents within tumor cells. TDK-HCPT can inhibit tumor growth, induce apoptosis of tumor cells, and has anti-tumor activity .

HY-156812

SM-360320 drug-linker	Toll-like Receptor (TLR)	Cancer
SM-360320 drug-linker (compound 19), a drug-linker of SM-360320 (HY-125390), is a small molecule immune agonist. SM-360320 drug-linker can be used to conjugated to PD-1 antibodies to form antibodies in resisting tumors .

HY-183162A

Glucose-PEG2000-NHS	Biochemical Assay Reagents	Others
Glucose-PEG2000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG2000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162D

Glucose-PEG10000-NHS	Biochemical Assay Reagents	Others
Glucose-PEG10000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG10000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162C

Glucose-PEG5000-NHS	Biochemical Assay Reagents	Others
Glucose-PEG5000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG5000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162B

Glucose-PEG3400-NHS	Biochemical Assay Reagents	Others
Glucose-PEG3400-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG3400-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162

Glucose-PEG1000-NHS	Biochemical Assay Reagents	Others
Glucose-PEG1000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG1000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

Cat. No.	상품명

HY-L105S

Peptide Compound Library	826 compounds
Peptides, composed of amino acids, serve as crucial building blocks for proteins and have gained significant attention in drug development over the past decade. The advancements in production, modification, and analytical technologies have led to a surge in the potential applications of peptides in medicine. Peptides offer a number of advantages over small molecule drugs, including: greater target specificity and efficacy, more predictable metabolic profiles, easier delivery to where they are needed in the body, and fewer side effects. Peptides are increasingly appearing in all branches of medicine as components of innovative drugs, imaging agents, diagnostic agents, and other complex drugs such as peptide-drug conjugates. To date, more than 80 peptide drugs have been approved to treat a variety of diseases, including microbial infections, obesity, anti-diabetes, and cancer, as well as to develop cell targeting platforms and improve cell penetration properties. MCE designs a unique collection of 826 peptide compounds. HY-L105S is a peptide compound library that can be provided with solution form based on HY-L105, and can be applied to peptides-based drug development.

Peptide Compound Library

826 compounds

Peptides, composed of amino acids, serve as crucial building blocks for proteins and have gained significant attention in drug development over the past decade. The advancements in production, modification, and analytical technologies have led to a surge in the potential applications of peptides in medicine. Peptides offer a number of advantages over small molecule drugs, including: greater target specificity and efficacy, more predictable metabolic profiles, easier delivery to where they are needed in the body, and fewer side effects. Peptides are increasingly appearing in all branches of medicine as components of innovative drugs, imaging agents, diagnostic agents, and other complex drugs such as peptide-drug conjugates. To date, more than 80 peptide drugs have been approved to treat a variety of diseases, including microbial infections, obesity, anti-diabetes, and cancer, as well as to develop cell targeting platforms and improve cell penetration properties.

MCE designs a unique collection of 826 peptide compounds. HY-L105S is a peptide compound library that can be provided with solution form based on HY-L105, and can be applied to peptides-based drug development.

HY-LD005

DEL D Kit Cyclic Peptide Library	1.2 billion compounds
Cyclic peptide library have advantages such as high affinity, high selectivity, and suitability for targeting protein–protein interactions. Through DEL synthesis technology, the library size can achieve hundreds of millions. DEL cyclic peptide library have advantages like low cost andhigh screeing efficiency, making them valuable for discovering lead compounds against challenging drug targets. This cyclic peptide library is constructed with unnatural amino acids as building block, synthesized through DNA-compatible chemical reactions. Each cyclic peptide consist of six amino acids and constrained conformations such as side-chain cross-linking, disulfide bonds, and macrocyclization. These cyclic peptides exhibit significantly improved stability and druggability compared with linear peptides, filling the gap between small molecules and macromolecular biologics. Each cyclic peptide is uniquely conjugated to a DNA barcode sequence for molecular identification and sequencing decoding. MCE’s cyclic peptide library has8 independent sub-libraries, with a total molecular diversity of 1.2 billion. It is constructed via multi-round combinatorial assembly of building blocks and diverse cyclization strategies, facilitating the discovery of cyclic peptide leads for undruggable targets.

DEL D Kit Cyclic Peptide Library

1.2 billion compounds

Cyclic peptide library have advantages such as high affinity, high selectivity, and suitability for targeting protein–protein interactions. Through DEL synthesis technology, the library size can achieve hundreds of millions. DEL cyclic peptide library have advantages like low cost andhigh screeing efficiency, making them valuable for discovering lead compounds against challenging drug targets.

This cyclic peptide library is constructed with unnatural amino acids as building block, synthesized through DNA-compatible chemical reactions. Each cyclic peptide consist of six amino acids and constrained conformations such as side-chain cross-linking, disulfide bonds, and macrocyclization. These cyclic peptides exhibit significantly improved stability and druggability compared with linear peptides, filling the gap between small molecules and macromolecular biologics. Each cyclic peptide is uniquely conjugated to a DNA barcode sequence for molecular identification and sequencing decoding.

MCE’s cyclic peptide library has8 independent sub-libraries, with a total molecular diversity of 1.2 billion. It is constructed via multi-round combinatorial assembly of building blocks and diverse cyclization strategies, facilitating the discovery of cyclic peptide leads for undruggable targets.

Cat. No.	상품명	Type

HY-141598

Datopotamab deruxtecan (solution) 2 Publications Verification DS-1062 (solution); Dato-DXd (solution)	Fluorescent Dyes
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

Datopotamab deruxtecan (solution)

2 Publications Verification

DS-1062 (solution); Dato-DXd (solution)

Fluorescent Dyes

Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

HY-13631EG

Deruxtecan MC-GGFG-DXD	Fluorescent Dyes
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-164729

FZ-AD005	Fluorescent Dyes
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

FZ-AD005

Fluorescent Dyes

FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-15579G

MMAF Monomethylauristatin F	Fluorescent Dyes
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

MMAF

Monomethylauristatin F

Fluorescent Dyes

MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-20336G

Mc-Val-Cit-PABC-PNP	Fluorescent Dyes
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	Fluorescent Dyes
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W087187G

DOTAGA-anhydride	Fluorescent Dyes
DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

DOTAGA-anhydride

Fluorescent Dyes

DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-128952G

Tesirine SG3249	Fluorescent Dyes
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

Tesirine

SG3249

Fluorescent Dyes

Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	Fluorescent Dyes
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

Cat. No.	상품명	Type

HY-13631EG

Deruxtecan MC-GGFG-DXD	Biochemical Assay Reagents
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-15579G

MMAF Monomethylauristatin F	Biochemical Assay Reagents
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

MMAF

Monomethylauristatin F

Biochemical Assay Reagents

HY-20336G

Mc-Val-Cit-PABC-PNP	Biochemical Assay Reagents
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	Biochemical Assay Reagents
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W087187G

DOTAGA-anhydride	Biochemical Assay Reagents
DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

DOTAGA-anhydride

Biochemical Assay Reagents

HY-128952G

Tesirine SG3249	Biochemical Assay Reagents
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

Tesirine

SG3249

Biochemical Assay Reagents

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	Biochemical Assay Reagents
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-183162A

Glucose-PEG2000-NHS

Biochemical Assay Reagents

Glucose-PEG2000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG2000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162D

Glucose-PEG10000-NHS

Biochemical Assay Reagents

Glucose-PEG10000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG10000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162C

Glucose-PEG5000-NHS

Biochemical Assay Reagents

Glucose-PEG5000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG5000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162B

Glucose-PEG3400-NHS

Biochemical Assay Reagents

Glucose-PEG3400-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG3400-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

HY-183162

Glucose-PEG1000-NHS

Biochemical Assay Reagents

Glucose-PEG1000-NHS is a conjugate composed of glucose, PEG chains, and an active ester (NHS). Glucose-PEG1000-NHS combines the targeted recognition capabilities of glucose with the ability to rapidly covalently react with molecules containing primary amines (such as proteins, peptides, and amino-modified small molecules) to form stable amide bonds in an NHS ester. This allows for applications such as constructing targeted drug delivery systems and modifying nanoparticles.

Targets Recommended: Drug Intermediate Drug Isomer Drug Derivative Small Interfering RNA (siRNA) Repulsive guidance molecule Drug Metabolite Antibody-Drug Conjugates (ADCs) ALCAM/CD166 Peptide-Drug Conjugates (PDCs) Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC ADC Linker

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-20336G

Mc-Val-Cit-PABC-PNP	ADC Linker	Cancer
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-15579G

MMAF Monomethylauristatin F	Microtubule/Tubulin ADC Payload	Cancer
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-13631EG

Deruxtecan MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .

HY-W087187G

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-128952G

Tesirine SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: